Safety analysis of whether axitinib (Inlida) can be used in combination with other anti-cancer drugs

Axitinib (Axitinib) is an oralVEGFR (vascular endothelial growth factor receptor) tyrosine kinase inhibitor, mainly used to treat advanced clear cell renal cell carcinoma. Since its mechanism of action is mainly to inhibit tumor angiogenesis, it is often considered to be used in combination with other anti-cancer drugs in clinical practice to improve efficacy or overcome drug resistance problems. However, the safety of combined medications needs to be carefully evaluated to avoid potential additive adverse effects or drug interactions.

In clinical practice, axitinib is often used in combination with immune checkpoint inhibitors (such asPD-1/PD-L1antibodies) or other targeted drugs. Studies have shown that the combination regimen may enhance the anti-tumor effect and improve the overall response rate and progression-free survival. However, because axitinib itself may cause hypertension, proteinuria, bleeding, and hand-foot syndrome, special attention should be paid to the additive risk of these side effects when used in combination, especially in patients with underlying cardiovascular disease or renal insufficiency.

The key to safety management is individualized dose adjustment and close monitoring. During the combined treatment, patients need to regularly monitor blood pressure, liver and kidney function, blood routine and urine protein, and timely adjust the dosage of axitinib and combined drugs based on the monitoring results. At the same time, doctors need to pay attention to potential drug interactions, such as CYP3A4 inhibitors or inducers that may affect the plasma concentration of axitinib, thereby increasing toxicity or reducing efficacy.

In addition, patient education is equally important as life management. Patients should maintain a regular schedule and a low-salt diet to control blood pressure while taking the medication, and promptly report any abnormal symptoms, such as obvious fatigue, bleeding or edema. Through standardized monitoring, side effect management and close cooperation between doctors and patients, the maximum efficacy of combined treatment with axitinib and other anti-cancer drugs can be achieved while ensuring safety.

Reference materials:https://www.drugs.com/